Literature DB >> 10632666

Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro.

C Brodskyn1, S M Beverley, R G Titus.   

Abstract

In this study we have compared the immune response of normal human cells cultured in vitro to two virulent strains of Leishmania major (CC1 and LV39), and to an avirulent vaccine strain (dhfr-ts-) made by targeted deletion of the essential gene DHFR-TS. We utilized an in vitro system in which naive T cells from normal human donors were primed with autologous Leishmania-infected macrophages. All three parasites infected macrophages and transformed into amastigotes within the cells. However, whereas LV39 and CC1 replicated in macrophages, dhfr-ts- did not. When peripheral blood lymphocytes (PBL) were stimulated with autologous macrophages infected with any of the three parasites, the lymphocytes produced a type-1-biased cytokine response. Finally, addition of IL-12 during the first stimulation period increased the production of interferon-gamma but decreased IL-5 secretion. On the other hand, anti-IL-12 resulted in the opposite effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10632666      PMCID: PMC1905512          DOI: 10.1046/j.1365-2249.2000.01122.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

Authors:  L C Afonso; T M Scharton; L Q Vieira; M Wysocka; G Trinchieri; P Scott
Journal:  Science       Date:  1994-01-14       Impact factor: 47.728

2.  A dhfr-ts- Leishmania major knockout mutant cross-protects against Leishmania amazonensis.

Authors:  P Veras; C Brodskyn; F Balestieri; L d Freitas; A Ramos; A Queiroz; A Barral; S Beverley; M Barral-Netto
Journal:  Mem Inst Oswaldo Cruz       Date:  1999 Jul-Aug       Impact factor: 2.743

3.  Isolation of human peripheral blood lymphocytes: modification of a double discontinuous density gradient of Ficoll-Hypaque.

Authors:  M H Goldrosen; P J Gannon; M Lutz; E D Holyoke
Journal:  J Immunol Methods       Date:  1977       Impact factor: 2.303

4.  Tumor necrosis factor (cachectin) in human visceral leishmaniasis.

Authors:  M Barral-Netto; R Badaró; A Barral; R P Almeida; S B Santos; F Badaró; D Pedral-Sampaio; E M Carvalho; E Falcoff; R Falcoff
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

5.  IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts.

Authors:  F P Heinzel; R M Rerko; F Hatam; R M Locksley
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

6.  Cytokine patterns in the pathogenesis of human leishmaniasis.

Authors:  C Pirmez; M Yamamura; K Uyemura; M Paes-Oliveira; F Conceição-Silva; R L Modlin
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Human T cell responses to gp63, a surface antigen of Leishmania.

Authors:  D M Russo; J M Burns; E M Carvalho; R J Armitage; K H Grabstein; L L Button; W R McMaster; S G Reed
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

8.  Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis.

Authors:  L C Afonso; P Scott
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

9.  Leishmania major-specific, CD4+, major histocompatibility complex class II-restricted T cells derived in vitro from lymphoid tissues of naive mice.

Authors:  A H Shankar; R G Titus
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

10.  Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.

Authors:  J P Sypek; C L Chung; S E Mayor; J M Subramanyam; S J Goldman; D S Sieburth; S F Wolf; R G Schaub
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  9 in total

1.  Genetic dissection of pyrimidine biosynthesis and salvage in Leishmania donovani.

Authors:  Zachary N Wilson; Caslin A Gilroy; Jan M Boitz; Buddy Ullman; Phillip A Yates
Journal:  J Biol Chem       Date:  2012-02-24       Impact factor: 5.157

Review 2.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

3.  Adenine aminohydrolase from Leishmania donovani: unique enzyme in parasite purine metabolism.

Authors:  Jan M Boitz; Rona Strasser; Charles U Hartman; Armando Jardim; Buddy Ullman
Journal:  J Biol Chem       Date:  2012-01-11       Impact factor: 5.157

4.  Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers.

Authors:  M M Pompeu; C Brodskyn; M J Teixeira; J Clarêncio; J Van Weyenberg; I C Coelho; S A Cardoso; A Barral; M Barral-Netto
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

5.  Characterization of the T-cell receptor Vbeta repertoire in the human immune response against Leishmania parasites.

Authors:  Jorge Clarêncio; Camila I de Oliveira; Glória Bomfim; Margarida M Pompeu; Maria Jania Teixeira; Theolis C Barbosa; Sebastião Souza-Neto; Edgar M Carvalho; Cláudia Brodskyn; Aldina Barral; Manoel Barral-Netto
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

6.  Effects of tropism and virulence of Leishmania parasites on cytokine production by infected human monocytes.

Authors:  A Meddeb-Garnaoui; H Zrelli; K Dellagi
Journal:  Clin Exp Immunol       Date:  2008-11-20       Impact factor: 4.330

7.  Protective immunity and vaccination against cutaneous leishmaniasis.

Authors:  Ifeoma Okwor; Zhirong Mou; Dong Liu; Jude Uzonna
Journal:  Front Immunol       Date:  2012-05-29       Impact factor: 7.561

8.  Leishmania infantum and Leishmania braziliensis: Differences and Similarities to Evade the Innate Immune System.

Authors:  Sarah de Athayde Couto Falcão; Tatiana M G Jaramillo; Luciana G Ferreira; Daniela M Bernardes; Jaime M Santana; Cecília B F Favali
Journal:  Front Immunol       Date:  2016-08-03       Impact factor: 7.561

9.  Deficiency of Leishmania phosphoglycans influences the magnitude but does not affect the quality of secondary (memory) anti-Leishmania immunity.

Authors:  Dong Liu; Ifeoma Okwor; Zhirong Mou; Stephen M Beverley; Jude E Uzonna
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.